Remus Pharmaceuticals Limited (NSE:REMUS)

Remus Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	107.3	118.2	72.3	47.2	30.38	11.49
Short-Term Investments	446.4	430.9	200.4	202.4	-	-
Cash & Short-Term Investments	553.7	549.1	272.7	249.6	30.38	11.49
Cash Growth	72.28%	101.36%	9.25%	721.54%	164.51%	38.30%
Accounts Receivable	1,318	1,398	1,080	1,153	48.48	29.15
Receivables	1,414	1,495	1,290	1,335	48.48	29.15
Inventory	745.2	720.6	515.6	431.1	2.87	15.89
Prepaid Expenses	-	4.6	3.2	0.4	0.49	0.07
Other Current Assets	298	177.2	131.9	107.7	31.22	20.34
Total Current Assets	3,011	2,946	2,214	2,123	113.44	76.94
Property, Plant & Equipment	179.5	178	70.2	48.6	25.13	3.09
Long-Term Investments	4,570	2,570	1,953	1,064	206.16	30.68
Goodwill	87.3	87.3	87.3	87.3	-	-
Other Intangible Assets	3.3	2.4	0.7	2.1	0.5	-
Long-Term Deferred Tax Assets	-	-	-	-	1.27	0.41
Other Long-Term Assets	24.5	2.1	1.2	5.9	0.12	47.49
Total Assets	7,876	5,787	4,326	3,331	346.61	158.6

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	727.5	760.4	712.9	937.1	35.31	46.73
Accrued Expenses	26.5	20.4	14.5	10.4	8.61	2.75
Short-Term Debt	-	170.4	171.2	83.4	6.38	-
Current Portion of Long-Term Debt	161.8	3.3	3.6	2.1	2.16	0.93
Current Portion of Leases	6.2	10.1	5.1	5.1	-	-
Current Income Taxes Payable	71.6	66.1	28.1	14.4	6.75	4.71
Other Current Liabilities	411	460.3	279.9	358.6	22.41	36.71
Total Current Liabilities	1,405	1,491	1,215	1,411	81.62	91.84
Long-Term Debt	57.7	56.7	33.3	30	70.89	0.99
Long-Term Leases	29.1	30.2	16.6	21.7	-	-
Pension & Post-Retirement Benefits	-	4.8	5.7	4.2	2.75	-
Long-Term Deferred Tax Liabilities	606	325.1	229	111.6	-	-
Other Long-Term Liabilities	7.3	1.4	1	0.4	-	-
Total Liabilities	2,105	1,909	1,501	1,579	155.26	92.82

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	117.8	117.8	58.9	14.7	10.85	10
Additional Paid-In Capital	-	504.3	504.3	504.7	41.65	-
Retained Earnings	-	871.1	571.9	337.1	138.86	55.78
Comprehensive Income & Other	5,240	2,017	1,424	720.4	-	-
Total Common Equity	5,358	3,510	2,559	1,577	191.36	65.78
Minority Interest	413.4	367.4	266.9	175.2	-	-
Shareholders' Equity	5,771	3,877	2,826	1,752	191.36	65.78
Total Liabilities & Equity	7,876	5,787	4,326	3,331	346.61	158.6

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	254.8	270.7	229.8	142.3	79.43	1.92
Net Cash (Debt)	298.9	278.4	42.9	107.3	-49.05	9.57
Net Cash Growth	85.31%	548.95%	-60.02%	-	-	73.48%
Net Cash Per Share	24.48	23.63	7.28	9.50	-6.00	1.20
Filing Date Shares Outstanding	10.4	11.78	11.66	11.78	8.68	8.68
Total Common Shares Outstanding	10.4	11.78	11.66	11.78	8.68	8.68
Working Capital	1,607	1,455	998.4	712.2	31.82	-14.9
Book Value Per Share	515.10	297.85	219.47	133.82	22.05	7.58
Tangible Book Value	5,267	3,420	2,471	1,488	190.85	65.78
Tangible Book Value Per Share	506.39	290.24	211.92	126.23	21.99	7.58
Buildings	-	3.3	3.3	3.3	3.28	-
Machinery	-	99.6	71.4	35.8	31.07	7.89
Construction In Progress	-	82.8	-	0.1	0.22	-

Data Source: S&P Global Market Intelligence Last updated: Sep 8, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 11, 2026

Data Sources Report a data error